HomeHealth

Health

Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates

Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates

September 13, 2022

EDWARDS LAUNCHES SAPIEN 3 ULTRA RESILIA VALVE FOLLOWING FDA APPROVAL

EDWARDS LAUNCHES SAPIEN 3 ULTRA RESILIA VALVE FOLLOWING FDA APPROVAL

September 13, 2022

Illumina Genomics Forum to Convene Leading Visionaries to Explore Architecting Health’s Radically New Infrastructure

Illumina Genomics Forum to Convene Leading Visionaries to Explore Architecting Health’s Radically New Infrastructure

September 13, 2022

More than 2,000 Biopharma Leaders Come Together at Veeva R&D and Quality Summit to Advance Drug Development

More than 2,000 Biopharma Leaders Come Together at Veeva R&D and Quality Summit to Advance Drug Development

September 13, 2022

Hound Labs Forms Strategic Agreement with Quest Diagnostics

Hound Labs Forms Strategic Agreement with Quest Diagnostics

September 13, 2022

Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer

Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer

September 12, 2022

Humanigen and SAHMRI Announce Expansion of the PREACH-M Study of Lenzilumab in CMML

Humanigen and SAHMRI Announce Expansion of the PREACH-M Study of Lenzilumab in CMML

September 12, 2022

Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna’s Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214

Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna’s Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214

September 12, 2022

Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors

Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors

September 12, 2022

Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022

Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022

September 10, 2022

« 1 … 101 102 103 104 105 … 123 »